We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Predicts Sickle Cell Severity

By LabMedica International staff writers
Posted on 15 Mar 2012
A simple blood test has been devised that can predict whether sickle cell patients are at high risk for painful complications of the disease. More...


The device measures how well blood samples flow through a microfluidic device, which could help doctors monitor sickle cell patients and determine the best course of treatment.

Scientists at Massachusetts Institute of Technology (MIT; Cambridge, MA, USA), collaborating with others, have developed a microfluidic system to measure changes in sickle cell blood flow after deoxygenation. The system included a microfluidic device with a capillary-sized channel that was diffusively coupled to a gas reservoir. This system allowed control over many parameters that mimic physiological conditions during vaso-occlusion, including channel size, blood pressure, and oxygen concentration.

The investigators compared blood samples taken from sickle cell patients who had or had not made an emergency trip to the hospital or received a blood transfusion within the previous 12 months. Tests were carried out with blood samples from 23 patients with severe disease and 6 patients with benign disease. They directed blood through a microchannel and lowered its oxygen concentration, which triggers sickle cells to jam and block blood flow. These conditions can produce a vaso-occlusive crisis.

Blood samples from patients with more benign disease showed a significantly slower decrease in the conductance after deoxygenation. Oxygen concentration of the gas phase was measured with a fiber optic sensor (Ocean Optics, Dunedin, FL, USA) connected to the outlet of the gas reservoir. No other existing measures of blood properties, including concentration of red blood cells, fraction of altered hemoglobin or white blood cell count, can make this kind of prediction of severe disease.

The authors concluded that the strong correlation between blood rheodynamics and the clinical outcomes in the study population provides a valuable tool for scientific discovery, drug development, and possibly for patient monitoring and clinical decision-making in sickle cell disease. The scientists have applied for a patent on the technology and are now working on developing it as a diagnostic tool. The study was published on February 29, 2012, in the journal Science Translational Medicine.

Related Links:

Massachusetts Institute of Technology
Ocean Optics



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.